The development of apalutamide for the treatment of prostate cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The development of apalutamide for the treatment of prostate cancer
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2020-10-02
DOI
10.1080/17460441.2021.1829588
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole Genome and Transcriptional Analysis of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Demonstrates Intra-Class Heterogeneity
- (2019) Rahul R. Aggarwal et al. MOLECULAR CANCER RESEARCH
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes
- (2019) Ronald de Vries et al. DRUG METABOLISM AND DISPOSITION
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
- (2019) Pedro Isaacsson Velho et al. EUROPEAN UROLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
- (2019) Daniel E. Spratt et al. CLINICAL CANCER RESEARCH
- Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
- (2019) Neeraj Agarwal et al. LANCET ONCOLOGY
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
- (2019) E J Small et al. ANNALS OF ONCOLOGY
- A review of prostate cancer treatment impact on the CNS and cognitive function
- (2019) Charles Ryan et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
- (2018) Athanasios E. Dellis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Androgen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Antiandrogens
- (2018) E. David Crawford et al. JOURNAL OF UROLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone health during endocrine therapy for cancer
- (2018) Tilman D Rachner et al. Lancet Diabetes & Endocrinology
- Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure
- (2018) Susan Slovin et al. JAMA Oncology
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
- (2018) Fred Saad et al. LANCET ONCOLOGY
- Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance
- (2018) Hyung L. Kim et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
- (2017) Shuang G. Zhao et al. JAMA Oncology
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison
- (2015) Brian D. Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population
- (2013) R. Jeffrey Karnes et al. JOURNAL OF UROLOGY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
- (2009) Qianben Wang et al. CELL
- Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
- (2009) Dana Bliuc JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started